PCNSL Clinical Trials

2 recruiting

Frequently Asked Questions

Common questions about PCNSL clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 114 of 14 trials

Recruiting
Phase 1

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Diffuse Large B-Cell Lymphoma (DLBCL)Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)+6 more
Nurix Therapeutics, Inc.572 enrolled62 locationsNCT05131022
Recruiting
Phase 2

Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab

Primary CNS Lymphoma (PCNSL)
The Lymphoma Academic Research Organisation60 enrolled13 locationsNCT06931652
Recruiting
Phase 2

A Multicenter Two-Cohort Study of Methotrexate, Rituximab, Sintilimab and Pirtobrutinib for Treatment-Naive PCNSL vs. Real-World Investigator-Selected Treatment (Observational Cohort)

Primary Central Nervous System LymphomaPCNSL
Tongji Hospital110 enrolled3 locationsNCT07350850
Recruiting
Phase 1

A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)

Primary Central Nervous System LymphomaCentral Nervous System LymphomaSecondary Central Nervous System Lymphoma+4 more
Memorial Sloan Kettering Cancer Center26 enrolled8 locationsNCT07082868
Recruiting
Phase 2

PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.

Primary Central Nervous System Lymphoma (PCNSL)Secondary Central Nervous System Lymphoma (SCNSL)
The First Affiliated Hospital with Nanjing Medical University50 enrolled1 locationNCT07410520
Recruiting
Phase 2

Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma

Diffuse Large B-Cell Lymphoma (DLBCL)Primary CNS Lymphoma (PCNSL)
Hyungwoo Cho12 enrolled1 locationNCT07062627
Recruiting

Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma

Diffuse Large B Cell LymphomaPrimary Central Nervous System Lymphoma (PCNSL)
Ting YANG20 enrolled1 locationNCT07188077
Recruiting
Phase 1

A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants

Primary Central Nervous System Lymphoma (PCNSL)
Ono Pharmaceutical Co. Ltd32 enrolled2 locationsNCT07198087
Recruiting
Not Applicable

Combination Regimen of Teniposide, PD-1 Monoclonal Antibody and Selinixor for Patients With Relapsed or Refractory PCNSL

Primary Central Nervous System Lymphoma (PCNSL)
The First Affiliated Hospital of Soochow University40 enrolled1 locationNCT07074470
Recruiting
Phase 2

High-Dose Gemcitabine, Busulfan, and Thiotepa Followed by ASCT in Primary Central Nervous System Lymphoma

Primary Central Nervous System Lymphoma (PCNSL)
Sichuan University34 enrolled1 locationNCT07014943
Recruiting
Not Applicable

Rituximab, Methotrexate, and Tepadina Induction Followed by Etoposide and Cytarabine Consolidation in Primary Central Nervous System Lymphoma

Primary Central Nervous System Lymphoma (PCNSL)CNS Lymphoma Treatment
FengYan Jin41 enrolled1 locationNCT06946407
Recruiting
Phase 1

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

Diffuse Large B-Cell Lymphoma (DLBCL)Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)+5 more
Nurix Therapeutics, Inc.248 enrolled16 locationsNCT04830137
Recruiting
Phase 2

NB02 (Poseltinib) Combined Rituximab and Lenalidomide in R/R PCNSL

Primary CNS Lymphoma (PCNSL)
NOBO Medicine33 enrolled10 locationsNCT06737250
Recruiting
Phase 1Phase 2

A Study of Pomadomide in Combination With Rituximab and Methotrexate for Newly-diagnosed Primary Central Nervous System Lymphoma

PCNSL
Second Affiliated Hospital, School of Medicine, Zhejiang University43 enrolled1 locationNCT06554561